



ASAM American Society of
Addiction Medicine

Moving Beyond the Barriers of Treating Opioid Use Disorder

Planning Committee Disclosure Information

Edwin Salsitz, MD, DFASAM, Mount Sinai Beth Israel – No Relevant Financial Disclosures

Debra R Newman, PA-C, MPAS, MPH, First Judicial District Court – No Relevant Financial Disclosures

Melinda M. Campopiano, MD, FASAM, JBS International, Inc. – No Relevant Financial Disclosures

ASAM CME Committee Reviewer

R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM – Does disclose

Ownership Interest (includes stock, stock options, patent or other intellectual property):

- Gilead Sciences
- Organon and Company
- Merck and Company
- Pfizer
- Amgen Company